Wladimiroff J W, Stewart P A, Reuss A, van Swaay E, Lindhout D, Sachs E S
Department of Obstetrics and Gynaecology, Academic Hospital Rotterdam-Dijkzigt, Erasmus University Rotterdam, The Netherlands.
Ultrasound Med Biol. 1988;14(8):657-60. doi: 10.1016/0301-5629(88)90022-1.
A total of 162 pregnant subjects using anticonvulsant drugs were examined for fetal congenital defects over a period of five years. In 138 of these subjects, alpha-feto-protein (AFP) levels were determined in amniotic fluid at 16 weeks of gestation to rule out spina bifida. In all instances, a fetal anomaly scan was performed between 18 and 20 weeks of gestation. AFP levels were always within the normal range; neonatal examination revealed no spina bifida; however, in seven newborns, a single, or multiple structural defect was established. Apart from cases of severe hydrocephaly, hypospadia, and radius aplasia, the anomalies were too small to be detected by present-day ultrasound equipment. Couples should be informed of the limitations of ultrasound in the early detection of structural defects previously associated with the use of anticonvulsant drugs.
在五年时间里,对162名使用抗惊厥药物的孕妇进行了胎儿先天性缺陷检查。在这些受试者中,有138人在妊娠16周时测定了羊水甲胎蛋白(AFP)水平,以排除脊柱裂。在所有情况下,均在妊娠18至20周之间进行了胎儿畸形扫描。AFP水平始终在正常范围内;新生儿检查未发现脊柱裂;然而,有7名新生儿被诊断出有单个或多个结构缺陷。除了严重脑积水、尿道下裂和桡骨发育不全的病例外,这些异常太小,无法被当今的超声设备检测到。应告知夫妇超声在早期检测先前与使用抗惊厥药物相关的结构缺陷方面的局限性。